The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Cannabis and psychosis/schizophrenia: human studies
Open accessAbstract
The association between cannabis use and psychosis has long been recognized. Recent advances in knowledge about cannabinoid receptor function have renewed interest in this association. Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. Also clear is that in individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. The mechanisms by which cannabinoids produce transient psychotic symptoms, while unclear may involve dopamine, GABA, and glutamate neurotransmission. However, only a very small proportion of the general population exposed to cannabinoids develop a psychotic illness. It is likely that cannabis exposure is a “component cause” that interacts with other factors to “cause” schizophrenia or a psychotic disorder, but is neither necessary nor sufficient to do so alone. Nevertheless, in the absence of known causes of schizophrenia, the role of component causes remains important and warrants further study. Dose, duration of exposure, and the age of first exposure to cannabinoids may be important factors, and genetic factors that interact with cannabinoid exposure to moderate or amplify the risk of a psychotic disorder are beginning to be elucidated. The mechanisms by which exposure to cannabinoids increase the risk for developing a psychotic disorder are unknown. However, novel hypotheses including the role of cannabinoids on neurodevelopmental processes relevant to psychotic disorders are being studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Rice, D., & Barone, S. (2000) · Environmental Health Perspectives · doi:10.1289/ehp.00108s3511 · Cited by 2,944
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Neuregulin 1 and Susceptibility to Schizophrenia
Stefansson, H., Petursson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,683
Whittington, M. A., Traub, R. D., & Jefferys, J. G. R. (1995) · Nature · doi:10.1038/373612a0 · Cited by 1,613
Role of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Gamma Oscillation by Synaptic Inhibition in a Hippocampal Interneuronal Network Model
Wang, X.-J., & Buzsáki, G. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06402.1996 · Cited by 1,563
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts
Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92620-1 · Cited by 1,166
Chemical constituents of marijuana: The complex mixture of natural cannabinoids
ElSohly, M. A., & Slade, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.011 · Cited by 1,094
Adolescent cortical development: A critical period of vulnerability for addiction
Crews, F., He, J., & Hodge, C. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.12.001 · Cited by 1,091
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,080
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Self-citationThe neurodevelopmental model of schizophrenia: update 2005
Rapoport, J. L., Addington, A. M., Frangou, S., & Psych, M. R. C. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001642 · Cited by 993
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Cannabis use and psychosis: A longitudinal population-based study
van Os, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf043 · Cited by 928
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871
BONE-MARROW TRANSPLANTATION IN A PATIENT WITH THE WISKOTT-ALDRICH SYNDROME
Bach, F., Albertini, R., Joo, P., Anderson, J., & Bortin, M. (1968) · The Lancet · doi:10.1016/s0140-6736(68)92672-x · Cited by 866
Regional and cellular fractionation of working memory
Goldman-Rakic, P. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13473 · Cited by 812
Cognitive Functioning of Long-term Heavy Cannabis Users Seeking Treatment
Solowij, N. (2002) · JAMA · doi:10.1001/jama.287.9.1123 · Cited by 798
Zahrt, J., Taylor, J. R., Mathew, R. G., & Arnsten, A. F. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08528.1997 · Cited by 796
Hall, W., & Solowij, N. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05021-1 · Cited by 772
Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H.-U., & van Os, J. (2005) · BMJ · doi:10.1136/bmj.38267.664086.63 · Cited by 765
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
Prefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997) · Nature · doi:10.1038/385634a0 · Cited by 710
A mechanism for generation of long-range synchronous fast oscillations in the cortex
Traub, R. D., Whittington, M. A., Stanford, I. M., & Jefferys, J. G. R. (1996) · Nature · doi:10.1038/383621a0 · Cited by 707
The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus
Monory, K., Massa, F., Egertová, M., Eder, M., Blaudzun, H., Westenbroek, R., Kelsch, W., Jacob, W., Marsch, R., Ekker, M., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.006 · Cited by 706
Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders
Linszen, D. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040017002 · Cited by 656
Neuropsychological Performance in Long-term Cannabis Users
Pope, H. G., Gruber, A. J., Hudson, J. I., Huestis, M. A., & Yurgelun-Todd, D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.909 · Cited by 655
Localization of cannabinoid receptor mRNA in rat brain
Matsuda, L. A., Bonner, T. I., & Lolait, S. J. (1993) · Journal of Comparative Neurology · doi:10.1002/cne.903270406 · Cited by 631 · cited 1×
“CB1Rs are also expressed in glutamatergic cortical principal neurons [7, 52, 113, 141, 142, 146, 159, 213].”
BackgroundD’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617
Self-citationCannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610 · cited 2×
“The reported effects of these drugs include anxiety and panic, fear and paranoia, amnesia, ‘‘loss of control’’, thought disturbances, feelings of unreality, apprehension, dissociation, depersonalization, dysphoria, difficulty concentrating, hallucinations, and other perceptual alterations (Marinol Product Monograph) […”
BackgroundDose-related neurocognitive effects of marijuana use
Bolla, K. I., Brown, K., Eldreth, D., Tate, K., & Cadet, J. L. (2002) · Neurology · doi:10.1212/01.wnl.0000031422.66442.49 · Cited by 608
Murphy, B. L., Arnsten, A. F., Goldman-Rakic, P. S., & Roth, R. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1325 · Cited by 590
Cannabis: pharmacology and toxicology in animals and humans
ADAMS, I. B., & MARTIN, B. R. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911115852.x · Cited by 570
Association of Neuregulin 1 with Schizophrenia Confirmed in a Scottish Population
Stefansson, H., Sarginson, J., Kong, A., Yates, P., Steinthorsdottir, V., Gudfinnsson, E., Gunnarsdottir, S., Walker, N., Petursson, H., Crombie, C., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/345442 · Cited by 559
Hardwiring the Brain: Endocannabinoids Shape Neuronal Connectivity
Berghuis, P., Rajnicek, A. M., Morozov, Y. M., Ross, R. A., Mulder, J., Urbán, G. M., Monory, K., Marsicano, G., Matteoli, M., Canty, A., et al. (2007) · Science · doi:10.1126/science.1137406 · Cited by 551
Drug abuse in schizophrenic patients: clinical correlates and reasons for use
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.224 · Cited by 547 · cited 1×
“In contrast, studies based on self-report of subjective effects suggest that schizophrenia patients use substances such as cannabis to ‘‘selfmedicate’’ negative symptoms, depression, and side-effects of antipsychotics, to relieve boredom, to provide stimulation, to ‘‘feel good’’, to ‘‘get high’’, or to ‘‘relax’’ and t…”
ResultEarly-onset cannabis use and cognitive deficits: what is the nature of the association?
Pope, H. G., Gruber, A. J., Hudson, J. I., Cohane, G., Huestis, M. A., & Yurgelun-Todd, D. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00334-4 · Cited by 543
Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations
Hájos, N., Katona, I., Naiem, S. S., Mackie, K., Ledent, C., Mody, I., & Freund, T. F. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00217.x · Cited by 533
The acute effects of cannabinoids on memory in humans: a review
Ranganathan, M., & D’Souza, D. C. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0508-y · Cited by 525
Self-citationHollister, L. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90030-4 · Cited by 497
Kawamura, Y., Fukaya, M., Maejima, T., Yoshida, T., Miura, E., Watanabe, M., Ohno-Shosaku, T., & Kano, M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4872-05.2006 · Cited by 489
Fried, P. A., Watkinson, B., & Gray, R. (2003) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(03)00029-1 · Cited by 458
The Environment and Schizophrenia: The Role of Cannabis Use
Henquet, C. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi027 · Cited by 454
The emerging functions of endocannabinoid signaling during CNS development
Harkany, T., Guzmán, M., Galve-Roperh, I., Berghuis, P., Devi, L. A., & Mackie, K. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.004 · Cited by 432
Hollister, L. E. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06862-0 · Cited by 419
The neurobiology and evolution of cannabinoid signalling
Elphick, M. R., & Egertova, M. (2001) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2000.0787 · Cited by 417
Mechanisms of Cannabinoid Inhibition of GABAASynaptic Transmission in the Hippocampus
Hoffman, A. F., & Lupica, C. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-07-02470.2000 · Cited by 399
Effects of (?)?9-trans-tetrahydrocannabinol in man
Isbell, H., Gorodetzsky, C. W., Jasinski, D., Claussen, U., Spulak, F. V., & Korte, F. (1967) · Psychopharmacologia · doi:10.1007/bf00401256 · Cited by 396
Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum
Bossong, M. G., van Berckel, B. N., Boellaard, R., Zuurman, L., Schuit, R. C., Windhorst, A. D., van Gerven, J. M. A., Ramsey, N. F., Lammertsma, A. A., & Kahn, R. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.138 · Cited by 392
Being stoned: a review of self‐reported cannabis effects
GREEN, B., KAVANAGH, D., & YOUNG, R. (2003) · Drug and Alcohol Review · doi:10.1080/09595230310001613976 · Cited by 390
Endocannabinoid signaling system and brain reward: emphasis on dopamine
GARDNER, E. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.032 · Cited by 387
Neural substrates of faulty decision-making in abstinent marijuana users
BOLLA, K., ELDRETH, D., MATOCHIK, J., & CADET, J. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.02.012 · Cited by 387
Specific attentional dysfunction in adults following early start of cannabis use
Ehrenreich, H., Kunert, H. J., Moeller, M. R., Poser, W., Schilling, L., Gigerenzer, G., Hoehe, M. R., & Rinn, T. (1999) · Psychopharmacology · doi:10.1007/s002130050892 · Cited by 387
Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
French, E. D., Dillon, K., & Wu, X. (1997) · NeuroReport · doi:10.1097/00001756-199702100-00014 · Cited by 374
Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
Gessa, G., Melis, M., Muntoni, A., & Diana, M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01442-8 · Cited by 370
Robbe, D., Alonso, G., Duchamp, F., Bockaert, J., & Manzoni, O. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00109.2001 · Cited by 366
Egertov�, M., & Elphick, M. R. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000626)422:2<159::aid-cne1>3.0.co;2-1 · Cited by 364
Do we still believe in the dopamine hypothesis? New data bring new evidence
Abi-Dargham, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004110 · Cited by 361
The Residual Cognitive Effects of Heavy Marijuana Use in College Students
Pope, H. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530310027028 · Cited by 350
The endogenous cannabinoid system and brain development
Fernández-Ruiz, J., Berrendero, F., Hernández, M. L., & Ramos, J. A. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01491-5 · Cited by 347
Early adolescent cannabis exposure and positive and negative dimensions of psychosis
Stefanis, N. C., Delespaul, P., Henquet, C., Bakoula, C., Stefanis, C. N., & Van Os, J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00806.x · Cited by 340
Substance abuse and the onset of schizophrenia
Hambrecht, M., & Häfner, H. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(95)00609-5 · Cited by 339
Cannabinoids reveal importance of spike timing coordination in hippocampal function
Robbe, D., Montgomery, S. M., Thome, A., Rueda-Orozco, P. E., McNaughton, B. L., & Buzsaki, G. (2006) · Nature Neuroscience · doi:10.1038/nn1801 · Cited by 333
Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus
Derkinderen, P., Valjent, E., Toutant, M., Corvol, J.-C., Enslen, H., Ledent, C., Trzaskos, J., Caboche, J., & Girault, J.-A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02371.2003 · Cited by 331
LUNDQVIST, T. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.02.017 · Cited by 331
Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning
Mulder, J., Aguado, T., Keimpema, E., Barabás, K., Ballester Rosado, C. J., Nguyen, L., Monory, K., Marsicano, G., Di Marzo, V., Hurd, Y. L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803545105 · Cited by 327
A Review of Psychoactive Substance Use and Abuse in Schizophrenia: Patterns of Drug Choice
SCHNEIER, F. R., & SIRIS, S. G. (1987) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198711000-00001 · Cited by 319
Collip, D., Myin-Germeys, I., & Van Os, J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm163 · Cited by 305
Henquet, C., Rosa, A., Krabbendam, L., Papiol, S., Faňanás, L., Drukker, M., Ramaekers, J. G., & van Os, J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301197 · Cited by 299
Berghuis, P., Dobszay, M. B., Wang, X., Spano, S., Ledda, F., Sousa, K. M., Schulte, G., Ernfors, P., Mackie, K., Paratcha, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509494102 · Cited by 291
Hermann, H., Marsicano, G., & Lutz, B. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00509-7 · Cited by 290
Auclair, N., Otani, S., Soubrie, P., & Crepel, F. (2000) · Journal of Neurophysiology · doi:10.1152/jn.2000.83.6.3287 · Cited by 290
Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons
Misner, D. L., & Sullivan, J. M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-16-06795.1999 · Cited by 285
Defective Adult Neurogenesis in CB1 Cannabinoid Receptor Knockout Mice
Jin, K., Xie, L., Kim, S. H., Parmentier-Batteur, S., Sun, Y., Mao, X. O., Childs, J., & Greenberg, D. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.2.204 · Cited by 273
Effects of Acute Smoked Marijuana on Complex Cognitive Performance
Hart, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00273-1 · Cited by 271
The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells
Aguado, T., Palazuelos, J., Monory, K., Stella, N., Cravatt, B., Lutz, B., Marsicano, G., Kokaia, Z., Guzmán, M., & Galve-Roperh, I. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3101-05.2006 · Cited by 269
Cannabis Use and Age at Onset of Schizophrenia
Veen, N. D., Selten, J.-P., van der Tweel, I., Feller, W. G., Hoek, H. W., & Kahn, R. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.501 · Cited by 266
Eggan, S. M., & Lewis, D. A. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhj136 · Cited by 264
Neuregulin-β induces expression of an NMDA-receptor subunit
Ozaki, M., Sasner, M., Yano, R., Lu, H. S., & Buonanno, A. (1997) · Nature · doi:10.1038/37795 · Cited by 257
Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey
Negrete, J. C., Knapp, W. P., Douglas, D. E., & Smith, W. B. (1986) · Psychological Medicine · doi:10.1017/s0033291700010278 · Cited by 254
Neurocognitive consequences of marihuana—a comparison with pre-drug performance
Fried, P. A., Watkinson, B., & Gray, R. (2005) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2004.11.003 · Cited by 253
Howlett, A. C., Johnson, M. R., Melvin, L. S., & Milne, G. M. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13196-9 · Cited by 253
Zhang, P.-W., Ishiguro, H., Ohtsuki, T., Hess, J., Carillo, F., Walther, D., Onaivi, E. S., Arinami, T., & Uhl, G. R. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001560 · Cited by 247
Gene-Environment Interplay Between Cannabis and Psychosis
Henquet, C., Di Forti, M., Morrison, P., Kuepper, R., & Murray, R. M. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn108 · Cited by 247
Presynaptic Modulation by Endocannabinoids
Lovinger, D. M. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-74805-2_14 · Cited by 246
Prenatal marijuana and alcohol exposure and academic achievement at age 10
Goldschmidt, L., Richardson, G. A., Cornelius, M. D., & Day, N. L. (2004) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2004.04.003 · Cited by 246
On the Plausibility of “The Neurodevelopmental Hypothesis” of Schizophrenia
Weinberger, D. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00199-n · Cited by 245
GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus
Katona, I., Sperlágh, B., Maglóczky, Z., Sántha, E., Köfalvi, A., Czirják, S., Mackie, K., Vizi, E. S., & Freund, T. F. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00286-4 · Cited by 244
Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
Javitt, D. (1987) · PubMed · Cited by 240
Abnormal brain activity in prefrontal brain regions in abstinent marijuana users
Eldreth, D. A., Matochik, J. A., Cadet, J. L., & Bolla, K. I. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.032 · Cited by 239
Genetic Dissection of Behavioural and Autonomic Effects of Δ9-Tetrahydrocannabinol in Mice
Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G., Wotjak, C. T., Lutz, B., & Marsicano, G. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050269 · Cited by 238
French, E. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00278-4 · Cited by 236
CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
Ujike, H., Takaki, M., Nakata, K., Tanaka, Y., Takeda, T., Kodama, M., Fujiwara, Y., Sakai, A., & Kuroda, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001029 · Cited by 228
Pistis, M., Ferraro, L., Pira, L., Flore, G., Tanganelli, S., Gessa, G. L., & Devoto, P. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03055-x · Cited by 227
Domenici, M. R., Azad, S. C., Marsicano, G., Schierloh, A., Wotjak, C. T., Dodt, H.-U., Zieglgänsberger, W., Lutz, B., & Rammes, G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0372-06.2006 · Cited by 224
MACHADO ROCHA, F. C., STÉFANO, S. C., DE CÁSSIA HAIEK, R., ROSA OLIVEIRA, L. M. Q., & DA SILVEIRA, D. X. (2008) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2008.00917.x · Cited by 223
Association of the NRG1 gene and schizophrenia: a meta-analysis
Munafò, M. R., Thiselton, D. L., Clark, T. G., & Flint, J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001817 · Cited by 221
Azad, S. C., Eder, M., Marsicano, G., Lutz, B., Zieglgänsberger, W., & Rammes, G. (2003) · Learning & Memory · doi:10.1101/lm.53303 · Cited by 220
Compton, D. R., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11216-0 · Cited by 215
A community survey of adverse effects of cannabis use
Thomas, H. (1996) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(96)01277-x · Cited by 215
Long‐term cannabis use: characteristics of users in an Australian rural area
Reilly, D., Didcott, P., Swift, W., & Hall, W. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9368375.x · Cited by 206
Cannabis, Vulnerability, and the Onset of Schizophrenia: An Epidemiological Perspective
Hambrecht, M., & Häfner, H. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2000.00736.x · Cited by 205
Andréasson, S., Allebeck, P., Engström, A., & Rydberg, U. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91823-5 · Cited by 202
The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia
Shoval, G., & Weizman, A. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.12.005 · Cited by 199
Green, A. I., Tohen, M. F., Hamer, R. M., Strakowski, S. M., Lieberman, J. A., Glick, I., & Scott Clark, W. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.08.001 · Cited by 195
Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study
VERDOUX, H., GINDRE, C., SORBARA, F., TOURNIER, M., & SWENDSEN, J. D. (2003) · Psychological Medicine · doi:10.1017/s0033291702006384 · Cited by 194
Psychotic Reactions Following Cannabis Use in East Indians
Chopra, G. S. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760070014002 · Cited by 193
Cannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192
Laviolette, S. R., & Grace, A. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0707-06.2006 · Cited by 189
Abstinent adolescent marijuana users show altered fMRI response during spatial working memory
Schweinsburg, A. D., Nagel, B. J., Schweinsburg, B. C., Park, A., Theilmann, R. J., & Tapert, S. F. (2008) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2007.04.018 · Cited by 187
Endocannabinoid functions controlling neuronal specification during brain development
Harkany, T., Keimpema, E., Barabás, K., & Mulder, J. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.011 · Cited by 186
Yang, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00112-2 · Cited by 184
Ames, F. (1958) · Journal of Mental Science · doi:10.1192/bjp.104.437.972 · Cited by 184
Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives
Talbott, J. A. (1969) · JAMA · doi:10.1001/jama.1969.03160280039006 · Cited by 181
Substance misuse at presentation to an early psychosis program
Van Mastrigt, S., Addington, J., & Addington, D. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0713-0 · Cited by 179
CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES
ROTTANBURG, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91270-3 · Cited by 178
The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation
Watson, S., Chambers, D., Hobbs, C., Doherty, P., & Graham, A. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.02.001 · Cited by 176
Cannabinoid receptor gene (CNR1): association with IV drug use
Comings, D. E., Muhleman, D., Gade, R., Johnson, P., Verde, R., Saucier, G., & MacMurray, J. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000247 · Cited by 175
Zammit, S., Spurlock, G., Williams, H., Norton, N., Williams, N., O'Donovan, M. C., & Owen, M. J. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.036129 · Cited by 174
Sullivan, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.3.1286 · Cited by 173
Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids
Diana, M., Melis, M., & Gessa, G. L. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00292.x · Cited by 173
Cannabinoids and prefrontal cortical function: Insights from preclinical studies
Egerton, A., Allison, C., Brett, R. R., & Pratt, J. A. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.12.002 · Cited by 172
The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus
Takahashi, K. A., & Castillo, P. E. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.024 · Cited by 171
Laviolette, S. R., & Grace, A. A. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6027-5 · Cited by 170
Hajós, M., Hoffmann, W. E., & Kocsis, B. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.12.005 · Cited by 170
Valjent, E., Pagès, C., Rogard, M., Besson, M., Maldonado, R., & Caboche, J. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01652.x · Cited by 168
Boucher, A. A., Arnold, J. C., Duffy, L., Schofield, P. R., Micheau, J., & Karl, T. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0721-3 · Cited by 168
Δ9-Tetrahydroeannabinol enhances presynaptic dopamine efflux In medial prefrontal cortex
Jianping, C., Paredes, W. M., Lowinson, J. H., & Gardner, E. L. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)94136-l · Cited by 166
Neurotrophins and schizophrenia
Buckley, P. F., Mahadik, S., Pillai, A., & Terry, A. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.025 · Cited by 166
Neuregulin 1 and schizophrenia
Stefánsson, H., Steinthórsdóttir, V., Thorgeirsson, T. E., Gulcher, J. R., & Stefánsson, K. (2004) · Annals of Medicine · doi:10.1080/07853890310017585 · Cited by 166
Reasons for substance use in schizophrenia
Addington, J., & Duchak, V. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09925.x · Cited by 166
Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis
McGuire, P. K., Jones, P., Harvey, I., Williams, M., McGuffin, P., & Murray, R. M. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00053-b · Cited by 165
Psychiatric Effects of Hashish
Tennant, F. S. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750250117016 · Cited by 164
Cannabis abuse and risk for psychosis in a prodromal sample
Kristensen, K., & Cadenhead, K. S. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.10.001 · Cited by 162
Ganja in Jamaica: A medical anthropological study of chronic marihuana use
Rubin, V. C., & Comitas, L. (1975) · De Gruyter eBooks · doi:10.1515/9783110812077 · Cited by 160
Schizophrenia in users and nonusers of cannabis: A longitudinal study in Stockholm County
Andréasson, S., Allebeck, P., & Rydberg, U. S. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb10296.x · Cited by 160
Cannabis use is associated with schizotypy and attentional disinhibition
Skosnik, P. D., Spatz-Glenn, L., & Park, S. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00132-8 · Cited by 160
CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids
McAllister, S. D., & Glass, M. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0344 · Cited by 159
Endogenous Cannabinoid Signaling
Piomelli, D., Beltramo, M., Giuffrida, A., & Stella, N. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0221 · Cited by 159
Jentsch, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00018-3 · Cited by 158
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 157
Association of a CB1 Cannabinoid Receptor Gene (CNR1) polymorphism with severe alcohol dependence
Schmidt, L. G., Samochowiec, J., Finckh, U., Fiszer-Piosik, E., Horodnicki, J., Wendel, B., Rommelspacher, H., & Hoehe, M. R. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00164-8 · Cited by 154
Psychological studies of marijuana and alcohol in man
Jones, R. T., & Stone, G. C. (1970) · Psychopharmacology · doi:10.1007/bf00402390 · Cited by 154
Influence of cannabis abuse on schizophrenic psychopathology
Peralta, V., & Cuesta, M. J. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb01456.x · Cited by 154
Miller, P. M., Lawrie, S. M., Hodges, A., Clafferty, R. A., Cosway, R., & Johnstone, E. C. (2001) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s001270170038 · Cited by 153
The Antagonism of Amphetamine-Induced Symptomatology by a Neuroleptic
Angrist, B., LEE, H. K., & Gershon, S. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.7.817 · Cited by 150
Evaluation of Intramuscular Levonantradol and Placebo in Acute Postoperative Pain
Jain, A. K., Ryan, J. R., McMahon, F. G., & Smith, G. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02610.x · Cited by 150
The Endocannabinoid System and Neurogenesis in Health and Disease
Galve‐Roperh, I., Aguado, T., Palazuelos, J., & Guzmán, M. (2007) · The Neuroscientist · doi:10.1177/1073858406296407 · Cited by 141
Heishman, S. J., Huestis, M. A., Henningfield, J. E., & Cone, E. J. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90028-g · Cited by 138
Marihuana and Temporal Disintegration
Melges, F. T., Tinklenberg, J. R., Hollister, L. E., & Gillespie, H. K. (1970) · Science · doi:10.1126/science.168.3935.1118 · Cited by 138
Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.
Jm, C., Kaplan, R. D., Szechtman, B., Szechtman, H., Gm, B., & Franco, S. (1991) · PubMed · Cited by 138
Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces
Chakrabarti, B., Kent, L., Suckling, J., Bullmore, E. T., & Baron‐Cohen, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04697.x · Cited by 136
Cannabis and psychotic illness
Mathers, D. C., & Ghodse, A. H. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.161.5.648 · Cited by 135
Cannabis use correlates with schizotypal personality traits in healthy students
Dumas, P., Saoud, M., Bouafia, S., Gutknecht, C., Écochard, R., Jean Dalery, A., Rochet, T., & d’Amato, T. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(01)00358-4 · Cited by 135
D’Souza, D. C., Braley, G., Blaise, R., Vendetti, M. S., Oliver, S., Pittman, B. P., Ranganathan, M., Bhakta, S. G., Zimolo, Z., Cooper, T. B., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1042-2 · Cited by 134
Self-citationDo cognitive impairments recover following cessation of cannabis use ?
Solowij, N. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00197-e · Cited by 133
D’Souza, D. C., Pittman, B. P., Perry, E. B., & Simen, A. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1333-2 · Cited by 133
Self-citationCannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County
Allebeck, P., Adamsson, C., Engström, A., & Rydberg, U. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03408.x · Cited by 132
Hollister, L. E. (1986) · PubMed · Cited by 130
Acute and Chronic Toxicity of Marijuana
Smith, D. E. (1968) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1968.10524399 · Cited by 125
Effects of Marihuana on Adolescents and Young Adults
Kolansky, H., & Moore, W. T. (1971) · JAMA · doi:10.1001/jama.1971.03180290062009 · Cited by 124
Pillai, A. (2008) · Neurosignals · doi:10.1159/000111562 · Cited by 124
Butovsky, E., Juknat, A., Goncharov, I., Elbaz, J., Eilam, R., Zangen, A., & Vogel, Z. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03074.x · Cited by 123
Effect of substance misuse in early psychosis
Addington, J., & Addington, D. E. (1998) · The British Journal of Psychiatry · doi:10.1192/s0007125000297791 · Cited by 121
Cannabinoid self-administration increases dopamine release in the nucleus accumbens
Fadda, P., Scherma, M., Spano, M. S., Salis, P., Melis, V., Fattore, L., & Fratta, W. (2006) · Neuroreport · doi:10.1097/01.wnr.0000236853.40221.8e · Cited by 118
Deciphering the Disease Process of Schizophrenia: The Contribution of Cortical Gaba Neurons
Lewis, D. A., & Hashimoto, T. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78004-7 · Cited by 117
Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample
Barkus, E., & Lewis, S. W. (2008) · Psychological Medicine · doi:10.1017/s0033291707002619 · Cited by 116
Leroy, S., Griffon, N., Bourdel, M., Olié, J., Poirier, M. F., & Krebs, M. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.10038 · Cited by 115
Meschler, J. P., & Howlett, A. C. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00012-0 · Cited by 107
D’Souza, D. C. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78010-2 · Cited by 105
Self-citationMcGuire, P. K., Jones, P. B., Harvey, I., Bebbington, P., Toone, B., Lewis, S. W., & Murray, R. M. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90097-3 · Cited by 104
Cannabis use correlates with schizotypy in healthy people
Williams, J. H., Wellman, N. A., & Rawlins, J. N. P. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.91686912.x · Cited by 104
Leweke, F. M., Schneider, U., Thies, M., Münte, T. F., & Emrich, H. M. (1999) · Psychopharmacology · doi:10.1007/s002130050884 · Cited by 102 · cited 1×
“[128] reported the effects of oral synthetic D(9)-THC (120 lg/kg) in 17 healthy individuals under controlled laboratory conditions.”
BackgroundEffects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation
Pistis, M., Porcu, G. S., Melis, M., Diana, M., & Gessa, G. L. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01612.x · Cited by 100
Malone, D. T., & TAYLOR, D. A. H. B. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702753 · Cited by 99
Arendt, M. C. B. B., Mortensen, P. B., Rosenberg, R., Pedersen, C. B., & Waltoft, B. L. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.11.1269 · Cited by 98
Chavarría‐Siles, I., Rojas, J. C., Hare, E., Walss‐Bass, C., Quezada, P., Dassori, A. M., Contreras, S. A., Medina, R., Ramírez, M., Salazar, R., et al. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30592 · Cited by 95
Moreau, J., & Peters, H. J. (1973) · Cited by 95
Martínez‐Gras, I., Hoenicka, J., Ponce, G., Rodríguez–Jiménez, R., Jiménez‐Arriero, M. Á., Pérez-Hernández, E., Ampuero, I., Ramos-Atance, J. A., Palomo, T., & Rubio, G. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0665-3 · Cited by 94
Cannabis Consumption as a Prognostic Factor in Schizophrenia
Mj, M., Calcedo-Ordonez, A., & Varo-Prieto, J. R. (1994) · The British Journal of Psychiatry · doi:10.1192/bjp.164.5.679 · Cited by 93
Degenhardt, L. J., Tennant, C. C., Gilmour, S., SCHOFIELD, D., Nash, L. M., Hall, W., & McKay, D. (2007) · Psychological Medicine · doi:10.1017/s0033291707009956 · Cited by 92
Corcoran, C. M., Kimhy, D., Stanford, A. D., Khan, S., Walsh‐Messinger, J., Thompson, J., Schobel, S., Harkavy‐Friedman, J., Goetz, R. R., Colibazzi, T., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.008 · Cited by 92
Neuregulin 1 Genotype and Schizophrenia
Munafo, M. R., Attwood, A. S., & Flint, J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm129 · Cited by 89
Isbell, H., & Jasinski, D. R. (1969) · Psychopharmacology · doi:10.1007/bf00403684 · Cited by 87
Symptoms of schizotypy precede cannabis use
Schiffman, J. E., Nakamura, B. J., Earleywine, M., & LaBrie, J. W. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2005.01.004 · Cited by 87
Boucher, A. A., Hunt, G. E., Karl, T., Micheau, J., McGregor, I. S., & Arnold, J. C. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.08.020 · Cited by 85
Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia
Tsai, S., Wang, Y.-C., & Hong, C. (2000) · Psychiatric Genetics · doi:10.1097/00041444-200010030-00008 · Cited by 83
Hooker, W. D., & Jones, R. T. (1987) · Psychopharmacology · doi:10.1007/bf00690920 · Cited by 82
Marks, D. F., & MacAvoy, M. G. (1989) · Psychopharmacology · doi:10.1007/bf00445566 · Cited by 77
Cited by
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 544
Seely, K. A., Lapoint, J., Moran, J. H., & Fattore, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.017 · Cited by 465
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112460109 · Cited by 462
Batalla, A., Bhattacharyya, S., Yücel, M., Fusar-Poli, P., Crippa, J. A., Nogué, S., Torrens, M., Pujol, J., Farré, M., & Martin-Santos, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055821 · Cited by 416
Toward a neurobiology of delusions
Corlett, P. R., Taylor, J. R., Wang, X.-J., Fletcher, P. C., & Krystal, J. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.007 · Cited by 394
Metadata
- Authors
- D’Souza, D. C., Sewell, R. A., & Ranganathan, M.
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2009-07-16
- Volume
- 259
- Issue
- 7
- Pages
- 413-431
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W2132835664
- Cited by
- 295
- References
- 234
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.